Please login to the form below

Not currently logged in
Email:
Password:

Eisai sets up new pharmaceutical marketing subsidiary in Belgium

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Eisai SA/NV is owned by Eisai Europe and will serve as the regional sales centre for Benelux countries, the sixth largest market in the EU. The subsidiary will begin marketing activities in the region, focusing on the anti-epileptic drugs Zonegran (zonisamide) and Inovelon (rufinamide). It will also start to market the non-opioid severe chronic infused pain drug Prialt (ziconotide), while also co-promoting Alzheimer's disease treatment Aricept (donepezil) in Belgium and Luxembourg with its partner, Pfizer.

Eisai says it will further expand its business operations across the EU and will undertake independent marketing activities by using its own sales and marketing personnel, tailored for each county.

Eisai SA/NV is Eisai's ninth marketing subsidiary in the EU region, bringing the total number of countries where Eisai has sales and marketing operations through its own distribution channels to 17. These include the UK, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands and Luxembourg.



28th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics